Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 0.40 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1029516 | 0.79 | CAMK2A (0.50) | ARLTA4HSTK39 | |
| SCHEMBL5536466 | 0.79 | LTA4H (0.51) | ARLTA4HPTGS2 | |
| SCHEMBL98414 | 0.77 | LTA4H (0.46) | LTA4HTSHR | |
| SCHEMBL1676646 | 0.77 | LTA4H (0.53) | ARLTA4HPTGS2TSHR | |
| SCHEMBL1554311 | 0.77 | LTA4H (0.41) | LTA4HTSHR | |
| SCHEMBL28534695 | 0.75 | AR (0.48) | ARLTA4HTSHRSTK39MGLL | |
| SCHEMBL28415142 | 0.74 | HTR2A (0.44) | AR | |
| SCHEMBL21697477 | 0.73 | PARP10 (0.54) | — | |
| SCHEMBL10543494 | 0.73 | LTA4H (0.41) | LTA4HTSHR | |
| SCHEMBL10546106 | 0.73 | CYP1A2 (0.44) | LTA4HTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-4814340-A | 1,4-diaryl alkane derivatives having insecticidal and acaricidal activity | MITSUI TOATSU CHEMICALS, INC. (JP) | 1989-03-21 | — | — | US | disclosed |
| US-4661501-A | Certain aryl-alkane-2-pyridyloxy-phenyl derivatives having insecticidal and acaricidal activity | MITSUI TOATSU CHEMICALS, INC. (JP) | 1987-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | AR 254/4885LTA4H 3452/4885PTGS2 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.